Please use this identifier to cite or link to this item:
|Title:||Genomic profile of breast cancer: cost<br>effectiveness analysis from the Spanish National Healthcare System perspective.|
|Author:||Seguí, M. A.|
Lluch Hernández, Ana
Chiavenna, S. M.
|Keywords:||Càncer de mama|
|Abstract:||Background: Cost<br>effectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was 7100, 6380 and 4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost<br>effective from year 7 versus online algorithm (lifetime: 1457 per quality-adjusted life years gained). Conclusions: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost<br>effective versus online algorithm.|
|Note:||Versió postprint del document publicat a: http://dx.doi.org/10.1586/14737167.2014.957185|
|It is part of:||Expert Review of Pharmacoeconomics & Outcomes Research, 2014, vol. 14, num. 6, p. 889-899|
|Appears in Collections:||Articles publicats en revistes (Genètica, Microbiologia i Estadística)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.